Literature DB >> 26334637

Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm.

Yoshihiro Miyasaka1, Takao Ohtsuka, Koji Tamura, Yasuhisa Mori, Koji Shindo, Daisuke Yamada, Shunichi Takahata, Kousei Ishigami, Tetsuhide Ito, Shoji Tokunaga, Yoshinao Oda, Kazuhiro Mizumoto, Masafumi Nakamura, Masao Tanaka.   

Abstract

OBJECTIVE: To identify factors predicting the development of high-risk lesions in the remnant pancreas after surgery for intraductal papillary mucinous neoplasm (IPMN).
BACKGROUND: IPMN has unique features, including multifocality, adenoma-carcinoma sequence, and the development of distinct pancreatic ductal adenocarcinoma (PDAC) in the same pancreas. Careful attention should, therefore, be paid to the metachronous occurrence of high-risk lesions, including high-grade dysplasia or invasive carcinoma (HGD/INV) of IPMN and concomitant PDAC in the remnant pancreas after partial pancreatectomy for IPMN.
METHODS: Clinicopathologic and surveillance data for 195 patients who underwent partial pancreatectomy for IPMN were reviewed retrospectively.
RESULTS: Thirteen patients exhibited metachronous development of high-risk lesions including 6 HGD/INV and 7 concomitant PDACs in the remnant pancreas. The 5- and 10-year cumulative incidences of metachronous high-risk lesions in the remnant pancreas were 7.8% and 11.8%, respectively. Twelve of 13 patients had high-risk lesions at the time of initial surgery, and 10 of the 13 IPMNs were located in the distal pancreas. The IPMN subtypes initially resected were gastric in 6 patients, intestinal in 5, and pancreatobililary in the remaining 2. Univariate and multiple regression analyses identified pathologic results of HGD/INV and IPMN located in the distal pancreas as independent predictive factors for metachronous HGD/INV of IPMN, and the pancreatobiliary subtype of IPMN and presence of concomitant PDAC for metachronous PDAC.
CONCLUSIONS: Patients undergoing partial pancreatectomy for IPMN are at high risk of developing lesions requiring surgery in the remnant pancreas, and close, long-term surveillance should be considered in these patients.

Entities:  

Mesh:

Year:  2016        PMID: 26334637     DOI: 10.1097/SLA.0000000000001368

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  19 in total

1.  Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.

Authors:  Antonio Pea; Jun Yu; Neda Rezaee; Claudio Luchini; Jin He; Marco Dal Molin; James F Griffin; Helen Fedor; Shahriar Fesharakizadeh; Roberto Salvia; Matthew J Weiss; Claudio Bassi; John L Cameron; Lei Zheng; Aldo Scarpa; Ralph H Hruban; Anne Marie Lennon; Michael Goggins; Christopher L Wolfgang; Laura D Wood
Journal:  Ann Surg       Date:  2017-07       Impact factor: 12.969

2.  Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society.

Authors:  Seiko Hirono; Yasuhiro Shimizu; Takao Ohtsuka; Toshifumi Kin; Kazuo Hara; Atsushi Kanno; Shinsuke Koshita; Keiji Hanada; Masayuki Kitano; Hiroyuki Inoue; Takao Itoi; Toshiharu Ueki; Toshio Shimokawa; Susumu Hijioka; Akio Yanagisawa; Masafumi Nakamura; Kazuichi Okazaki; Hiroki Yamaue
Journal:  J Gastroenterol       Date:  2019-08-28       Impact factor: 7.527

Review 3.  [Resection of main duct and mixed type IPMN ≥5 mm].

Authors:  G O Ceyhan; F Scheufele; H Friess
Journal:  Chirurg       Date:  2017-11       Impact factor: 0.955

Review 4.  Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Takao Ohtsuka; Takahiro Tomosugi; Ryuichiro Kimura; So Nakamura; Yoshihiro Miyasaka; Kohei Nakata; Yasuhisa Mori; Makiko Morita; Nobuhiro Torata; Koji Shindo; Kenoki Ohuchida; Masafumi Nakamura
Journal:  Surg Today       Date:  2019-03-16       Impact factor: 2.549

Review 5.  Early Detection of Pancreatic Cancer: Opportunities and Challenges.

Authors:  Aatur D Singhi; Eugene J Koay; Suresh T Chari; Anirban Maitra
Journal:  Gastroenterology       Date:  2019-02-02       Impact factor: 22.682

Review 6.  Resection of Recurrent Pancreatic Cancer: Who Can Benefit?

Authors:  Henrik Nienhüser; Markus W Büchler; Martin Schneider
Journal:  Visc Med       Date:  2021-11-11

7.  Natural History of Patients Followed Radiographically with Mucinous Cysts of the Pancreas.

Authors:  Linda M Pak; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; Vinod P Balachandran; William R Jarnagin; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2017-05-17       Impact factor: 3.452

8.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: Strategic Considerations.

Authors:  Vicente Morales-Oyarvide; Zhi Ven Fong; Carlos Fernández-Del Castillo; Andrew L Warshaw
Journal:  Visc Med       Date:  2017-12-08

9.  Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report.

Authors:  Mark Steven Miller; Peter Allen; Teresa A Brentnall; Michael Goggins; Ralph H Hruban; Gloria M Petersen; Chinthalapally V Rao; David C Whitcomb; Randall E Brand; Suresh T Chari; Alison P Klein; David M Lubman; Andrew D Rhim; Diane M Simeone; Brian M Wolpin; Asad Umar; Sudhir Srivastava; Vernon E Steele; Jo Ann S Rinaudo
Journal:  Pancreas       Date:  2016-09       Impact factor: 3.327

Review 10.  Comparison of guidelines for intraductal papillary mucinous neoplasm: What is the next step beyond the current guidelines?

Authors:  Masafumi Nakamura; Yoshihiro Miyasaka; Yoshihiko Sadakari; Kenjiro Date; Takao Ohtsuka
Journal:  Ann Gastroenterol Surg       Date:  2017-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.